PCI Synthesis

PCI Synthesis is a leading Pharmaceutical CDMO (Contract Development and Manufacturing Organization) and is the largest small molecule drug substance manufacturer in the New England area. The company provides its pharmaceutical and biotechnology customers with a comprehensive range of development and manufacturing services for new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs) and other specialty products.

has been acquired by

Pharmaceutical CDMO

Situation

BlackArch was retained by PCI Synthesis to advise the company on its sale given BlackArch’s extensive experience and global reach in the pharmaceutical CDMO sector.

BlackArch’s Customized Solution

BlackArch designed and executed a highly efficient and global sale process and aggressively positioned the company’s unique capabilities and strong momentum.

Outcome

PCI Synthesis was acquired by Novacap, a global player in pharmaceutical synthesis headquartered near Lyon, France, that operates 28 industrial plants and employs more than 3,000 people across the world. PCI, the first acquisition by Novacap in the U.S., will be Novacap’s lead U.S. company and the combination provides PCI Synthesis with additional resources to continue its development while reinforcing Novacap’s global leadership in pharmaceutical synthesis.

Industries:

Life Science & Healthcare

Location:

Newburyport, MA

Transaction type:

Sellside Advisory